[1]罗 婷,段蕴枭,钟 浩,等.急性髓系白血病患者血清miR-24，miR-106a 水平表达及其临床诊断价值[J].现代检验医学杂志,2024,39(05):1-5+68.[doi:10.3969/j.issn.1671-7414.2024.05.001]
　LUO Ting,DUAN Yunxiao,ZHONG Hao,et al.Expression of Serum miR-24 and miR-106a Levels in Patients with Acute Myeloid Leukemia and Its Clinical Diagnostic Value[J].Journal of Modern Laboratory Medicine,2024,39(05):1-5+68.[doi:10.3969/j.issn.1671-7414.2024.05.001]
点击复制

急性髓系白血病患者血清miR-24，miR-106a 水平表达及其临床诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年05期
页码:
1-5+68
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Expression of Serum miR-24 and miR-106a Levels in Patients with Acute Myeloid Leukemia and Its Clinical Diagnostic Value
文章编号:
1671-7414（2024）05-001-06
作者:
罗 婷; 段蕴枭; 钟 浩; 沈 恺
（四川大学华西医院血液内科\ 四川大学华西护理学院，成都 610041）
Author(s):
LUO Ting;  DUAN Yunxiao;  ZHONG Hao;  SHEN Kai
（Department of Hematology, West China Hospital,Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, China）
关键词:
急性髓系白血病; 微小RNA-24; 微小RNA-106a; 临床病理特征
分类号:
R557；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.05.001
文献标志码:
A
摘要:
目的 探究急性髓系白血病（acute myeloid leukemia, AML）患者血清微小RNA（micro RNA，miR）-24，miR-106a 水平表达及其临床诊断价值。方法 选取四川大学华西医院2018 年6 月～ 2020 年6 月收治的急性髓系白血病患者98 例作为研究组，根据疗效将患者分为完全缓解组、部分缓解组和未缓解组，另选取同期健康体检者98 例作为对照组；血清miR-24，miR-106a 采用qRT-PCR 检测；采用Kaplan-Meier 生存曲线分析miR-24，miR-106a 与急性髓系白血病患者预后的关系；受试者工作特征（ROC）曲线分析血清miR-24，miR-106a 对急性髓系白血病患者的诊断价值。结果 与对照组相比，研究组血清miR-24 表达水平（0.62±0.16 vs 1.01±0.21）显著降低，miR-106a 表达水平（1.64±0.38vs 1.02±0.24）显著升高，差异具有统计学意义（t=14.624，13.656，均P ＜ 0.05）。完全缓解组、部分缓解组和未缓解组血清miR-24 水平依次降低，血清miR-106a 水平依次升高，差异具有统计学意义（F=65.207，24.280，均P ＜ 0.05）。miR-24，miR-106a 表达水平与脾肿大和WBC 有关（χ2=5.029，6.153；9.216，8.151，均P ＜ 0.05）。miR-24 高表达组生存率显著高于低表达组（59.57% vs 39.22%，χ2=9.851，P ＜ 0.05），miR-106a 高表达组生存率显著低于低表达组（38.00%vs 60.42%，χ2=21.728，P ＜ 0.05）。根据ROC 曲线得知，血清miR-24，miR-106a 诊断急性髓系白血病患者的曲线下面积（AUC）分别为0.894，0.880，二者联合诊断急性髓系白血病患者的AUC 为0.929，二者联合诊断优于各自单独诊断（Z=2.624，2.735，均P ＜ 0.05）。结论 急性髓系白血病患者血清miR-24 水平显著升高，miR-106a 水平显著降低，二者联合检测可提高其诊断价值。
Abstract:
Objective To investigate the expression of serum micro RNA (miR)-24, miR-106a levels and their clinical diagnostic value in patients with acute myeloid leukemia(AMI). Methods A sum of 98 patients with AML admitted to West China Hospital of Sichuan University from June 2018 to June 2020 were selected as the study group. These patients were separated into complete remission group, partial remission group, and non remission group based on their efficacy. Meanwhile, another 98 patients undergoing physical examination were regarded as the control group. Serum miR-24 and miR-106a were detected using qRTPCR. Kaplan-Meier survival curve was applied to analyze the relationship between the levels of miR-24, miR-106a, and the prognosis of AML patients. Receiver operating characteristic (ROC) curve was applied to analyze the diagnostic value of serum miR-24 and miR-106a in patients with AML. Results Compared with the control group, serum miR-24 expression level (0.62±0.16 vs 1.01±0.21) was lower, but miR-106a expression level (1.64±0.38 vs 1.02±0.24) was higher in the study group, with significant differences (t=14.624, 13.656, all P<0.05). The serum miR-24 level was sequentially decreased, but the serum miR-106a level was sequentially increased in the complete remission, partial remission and non-remission groups, with significant differences (F=65.207, 24.280, all P<0.05). The expression levels of miR-24 and miR-106a were related to splenomegaly and WBC (χ2=5.029, 6.153; 9.216, 8.151, all P<0.05). The survival rate of the miR-24 high expression group was higher than that of the low expression group (59.57% vs 39.22%, χ2=9.851, P<0.05), but the survival rate of the miR-106a high expression group was lower than that of the low expression group (38.00% vs 60.42%, χ2=21.728, P<0.05). According to the ROC curve, the areas under the curve (AUC) for diagnosing AML patients with serum miR-24 and miR-106a were 0.894 and 0.880, respectively. The AUC of patients with acute myeloid leukemia diagnosed by the combination of the two was 0.929, which was superior to their respective individual diagnoses (Z=2.624, 2.735, all P<0.05). Conclusion The serum miR-24 level is increased, but miR-106a level is reduced in patients with acute myeloid leukemia. The combination of the two can improve its diagnostic value.

参考文献/References:

[1] BLOOMFIELD C D, ESTEY E, PLEYER L, et al. Time to repeal and replace response criteria for acute myeloid leukemia?[J]. Blood Reviews, 2018, 32(5): 416-425.
[2] 刘睿, 王玉明. 竞争性内源性RNA 在急性髓系白血病中的研究进展[J]. 现代检验医学杂志, 2022,37(3): 198-204. LIU Rui, WANG Yuming. Research progress of competitive endogenous RNA in acute myeloid leukemia[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 198-204.
[3] JONGEN-LAVRENCIC M, GROB T, HANEKAMP D, et al. Molecular minimal residual disease in acute myeloid leukemia[J]. New England Journal of Medicine, 2018, 378(13): 1189-1199.
[4] 张蕾, 刘英, 王欢, 等. 血清miR-203, miR-217 表达与急性髓系白血病患者预后的关系[J]. 现代生物医学进展, 2022, 22(9): 1743-1748. ZHANG Lei, LIU Ying, WANG Huan, et al. Relationship between the expression of serum miR-203 and miR-217 and the efficacy and prognosis of patients with acute myeloid leukemia[J]. Progress in Modern Biomedicine, 2022, 22(9): 1743-1748.
[5] GUO Tianya, ZHANG Jinbi, YAO Wang, et al. CircINHA resists granulosa cell apoptosis by upregulating CTGF as a ceRNA of miR-10a-5p in pig ovarian follicles[ J]. Biochimica et Biophysica Acta. Gene Regulatory Mechanismsh, 2019, 1862(10): 194420.
[6] 何哲炜, 郭文坚. 外泌体源性微小RNA 在急性髓细胞白血病中的研究现状[J]. 国际输血及血液学杂志,2020, 43(1): 23-26. HE Zhewei, GUO Wenjian. Research status of exosome-derived microRNA in acute myeloid leukemia[J]. International Journal of Blood Transfusion and Hematology, 2020, 43(1): 23-26.
[7] ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
[8] 张之南, 沈悌. 血液病诊断及疗效标准[J]. 3 版. 北京: 科学出版社, 2007: 131-134. ZHANG Zhinan, SHEN Ti. Diagnostic and therapeutic criteria for hematologic diseases[J]. 3th Ed. Beijing: Science Press, 2007: 131-134.
[9] 全海薇, 张亚丽, 王涵, 等. 急性髓系白血病患者外周血外泌体中miR-4286 表达水平检测及其诊断价值[J]. 吉林大学学报 ( 医学版), 2023, 49(2): 460-466. QUAN Haiwei, ZHANG Yali, WANG Han, et al. Detection of expression level of miR-4286 in exosome in peripheral blood of patients with acute myeloid leukemia and its diagnostic value[J]. Journal of Jilin University (Medicine Edition), 2023, 49(2): 460-466.
[10] 王亚南, 赵晶晶, 李凤莉, 等. 血清相关细胞因子水平检测在急性髓系白血病患者疗效评估、复发率预测中的应用价值[J]. 河南医学研究, 2022, 31(17):3100-3103. WANG Yanan, ZHAO Jingjing, LI Fengli, et al. Application value of serum-associated cytokine level assay in the assessment of efficacy and prediction of relapse rate in patients with acute myeloid leukemia[J]. Henan Medical Research, 2022, 31(17): 3100-3103.
[11] 冯砚平. 急性髓系白血病患者血清sPD-L1, OPN 水平与疗效及VEGF 的关系研究[J]. 检验医学与临床,2021, 18(15): 2148-2151. FENG Yanping. Study on relationship between the levels of serum sPD-L1 and OPN with curative effect and VEGF in patients with acute myeloid leukemia[J]. Laboratory Medicine and Clinic, 2021, 18(15): 2148- 2151.
[12] ZHANG Jinjin, REN Juchao, HAO Shengjie, et al. MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer[J]. American Journal of Translational Research, 2018, 10(2): 525- 534.
[13] LIN Yang, CAO Huifang, TIAN Yuxin, et al. MiR-24- 3p stimulates migration, invasion and proliferation of prostate cancer cells by targeting suppressor of cytokine signaling 6[J]. International Journal of Clinical and Experimental Pathology, 2018, 11(3): 1803-1810.
[14] LI Xiaohui, HAN Xingtao, WEI Pengtao, et al. Knockdown of LncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24- 3p and FSCN1[J]. Cancer Biology & Therapy, 2020, 21(5): 452-462.
[15] 秦伟, 蔡晓辉, 韩文敏, 等. 长链非编码RNA C9ORF139靶向miR-24-3P/TAOK1 调控急性髓系白血病细胞增殖的作用和机制[J]. 中华医学杂志, 2022, 102(8):576-583. QIN Wei, CAI Xiaohui, HAN Wenmin, et al. The role and mechanism of LncRNA C9ORF139 targeting miR- 24-3P/TAOK1 in regulating the proliferation of acute myeloid leukemia cells[J]. National Medical Journal of China, 2022, 102(8): 576-583.
[16] 杨卫东, 阮建波, 周湧, 等. MAFG-AS1 调控miR-24-3p 对急性淋巴细胞白血病细胞Molt4 增殖及凋亡的影响[J]. 免疫学杂志, 2022, 38(8): 673-680. YANG Weidong, RUAN Jianbo, ZHOU Yong, et al. MAFG-AS1 regulates the effect of miR-24-3p on the proliferation and apoptosis of acute lymphoblastic leukemia cells Molt4[J]. Immunological Journal, 2022, 38(8): 673-680.
[17] 康博雄, 李海龙, 陈彻, 等. miR-106a-5p 在胃癌细胞和胃癌组织中的表达及其调控靶基因信号通路富集分析[J]. 中国普外基础与临床杂志, 2018, 25(8):923-928. KANG Boxiong, LI Hailong, CHEN Che, et al. Expression of miR-106a-5p in gastric cancer cells and gastric cancer tissue and analysis of enriched pathway of target genes[J]. Chinese Journal of Bases and Clinics in General Surgery, 2018, 25(8): 923-928.
[18] JIAO Xuelong, LU Jie, HUANG Yichuan, et al. Long non-coding RNA H19 May be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer[J]. Cancer Biomarkers, 2019, 26(2):203-207.
[19] 张宁, 蔺刘亚, 李思繁, 等. miR-106a 靶向调控TIMP2 对人胃癌细胞增殖、转移及EMT 的影响[J].实用肿瘤学杂志, 2022, 36(2): 105-110. ZHANG Ning, LIN Liuya, LI Sifan, et al. Effects of miR-106a targeting TIMP2 on proliferation,metastasis and EMT of human gastric cancer[J]. Practical Oncology Journal, 2022, 36(2): 105-110.
[20] 杨青彦, 刘君毅, 梁亚林, 等. 肾细胞癌患者血清miRNA-106a 表达水平与临床病理特征和预后的关系[J]. 中华医学遗传学杂志, 2021, 38(7): 652-655. YANG Qingyan, LIU Junyi, LIANG Yalin, et al. Correlation between serum level of miRNA-106a expression with clinicopathological characteristics and prognosis of patients with renal cell carcinoma[J]. Chinese Journal of Medical Genetics, 2021, 38(7): 652- 655.
[21] 张彦芬, 高大, 易媛媛, 等. Pae 下调miR-106a-5p/PTEN 对白血病细胞增殖、凋亡的影响[J]. 现代免疫学, 2021, 41(1): 14-23. ZHANG Yanfen, GAO Da, YI Yuanyuan, et al. The effect of paeonol on the proliferation and apoptosis of leukemia cells by down-regulating miR-106a-5p/PTEN[J]. Current Immunology, 2021, 41(1): 14-23.

相似文献/References:

[1]张灵玲,张朝明,谢国丽.中性粒VCS参数表达的性别差及差异表达的临床应用[J].现代检验医学杂志,2015,30(06):86.[doi:10.3969/j.issn.1671-7414.2015.06.025]
　ZHANG Ling-ling,ZHANG Chao-ming,XIE Guo-li.Gender Differences of Neutrophil VCS Parameter Expression and Clinical Application of Differential Expression[J].Journal of Modern Laboratory Medicine,2015,30(05):86.[doi:10.3969/j.issn.1671-7414.2015.06.025]
[2]郑源海,林元峰,许瑞元,等.急性髓系白血病免疫表型特征与预后相关性分析[J].现代检验医学杂志,2018,33(04):90.[doi:10.3969/j.issn.1671-7414.2018.04.024]
　ZHENG Yuan-hai,LIN Yuan-feng,XU Rui-yuan,et al.Correlative Analysis of Immunophenotypic Characteristics and Prognosis in Acute Myeloid Leukemia[J].Journal of Modern Laboratory Medicine,2018,33(05):90.[doi:10.3969/j.issn.1671-7414.2018.04.024]
[3]范臻佳,金丽兰,史册,等.急性髓系白血病患者外周血粒细胞、单核细胞膜GPI锚链和红细胞表面CD59表达水平的研究[J].现代检验医学杂志,2019,34(01):26.[doi:10.3969/j.issn.1671-7414.2019.01.007]
　FAN Zhen-jia,JIN Li-lan,SHI Ce,et al.Expression Level of Peripheral Blood Granulocytes and Monocytes GPI Anchor Chain and Erythrocyte CD59 in AML Patients[J].Journal of Modern Laboratory Medicine,2019,34(05):26.[doi:10.3969/j.issn.1671-7414.2019.01.007]
[4]李　悦,徐焕铭,樊　华.基于TCGA 数据对60 岁以上不同分层急性髓系白血病患者相关lncRNA 的基因信息学分析[J].现代检验医学杂志,2020,35(03):20.[doi:10.3969/j.issn.1671-7414.2020.03.005]
　LI Yue,XU Huan-ming,FAN Hua.Genetic Informatics Analysis of lncRNA Related to Patients with Different Stratified Acute Myeloid Leukemia Over 60 Years Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(05):20.[doi:10.3969/j.issn.1671-7414.2020.03.005]
[5]张梦娜,李文生.髓过氧化物酶在淋巴造血系统疾病表达的最新研究进展[J].现代检验医学杂志,2022,37(02):195.[doi:10.3969/j.issn.1671-7414.2022.02.039]
　ZHANG Meng-na,LI Wen-sheng.Recent Research Progress of Myeloperoxidase Expression in Lymphatic Hematopoietic Diseases[J].Journal of Modern Laboratory Medicine,2022,37(05):195.[doi:10.3969/j.issn.1671-7414.2022.02.039]
[6]萧杏贤,刘　德,姜朝晖.AML不同疾病阶段患者T细胞耗竭及相关细胞因子表达水平实验研究[J].现代检验医学杂志,2022,37(03):138.[doi:10.3969/j.issn.1671-7414.2022.03.029]
　XIAO Xing-xian,LIU De,JIANG Zhao-hui.Experimental Study on T Cell Exhaustion and Related Cytokine Expression Levels in Patients with AML at Different Disease Stages[J].Journal of Modern Laboratory Medicine,2022,37(05):138.[doi:10.3969/j.issn.1671-7414.2022.03.029]
[7]刘　睿,王玉明.竞争性内源性RNA在急性髓系白血病中的研究进展[J].现代检验医学杂志,2022,37(03):198.[doi:10.3969/j.issn.1671-7414.2022.03.041]
　LIU Rui,WANG Yuming.Research Progress of Competitive Endogenous RNA in Acute Myeloid Leukemia[J].Journal of Modern Laboratory Medicine,2022,37(05):198.[doi:10.3969/j.issn.1671-7414.2022.03.041]

备注/Memo

备注/Memo:
基金项目：四川省自然科学基金项目（2022NSFSC1463）。
作者简介：罗婷（1985-），女，本科，医师，研究方向：内科学，E-mail：tn2884v@163.com。
通讯作者：沈恺（1987-），男，博士，主治医师，研究方向：白血病的临床和基础研究。
更新日期/Last Update: 2024-09-15